Following is a statement from the American Cancer Society Cancer Action Network (ACS CAN) commending the Food and Drug Administration (FDA) for finalizing its order to reclassify indoor tanning devices from a class I to a class II medical device, imposing greater control over their manufacture and distribution.
WASHINGTON May 16, 2014 Critical legislation introduced last night in the U.S. Senate would ensure that cost is not a barrier for Medicare beneficiaries trying to access lifesaving colon cancer screenings.
Following is a statement from Chris Hansen, president of the American Cancer Society Cancer Action Network (ACS CAN), on the Senate Health, Education, Labor, and Pensions (HELP) Committee hearing today on the state of tobacco regulation by the Food & Drug Administration (FDA).
An article posted today in the New England Journal of Medicine confirms what public health advocates have suspected for decades that chemicals used to flavor popular candies and drinks are strikingly similar to those used to flavor tobacco products that are designed to addict kids.
Today 's Senate Special Committee on Aging hearing on the fight against cancer represents the first time in more than five years that Congress has focused specific attention on a disease expected to kill more than 585,000 people in America and cost the economy an estimated $216 billion this year.
The information issued today provides much-needed clarity to plans and insurers on what constitutes a comprehensive tobacco cessation benefit under the Affordable Care Act.
American Cancer Society Chief Cancer Control Officer Richard Wender, M.D., testified at the Centers for Medicare & Medicaid Services Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) meeting today encouraging the agency to include Low Dose Computed Tomography (LDCT) scans for lung cancer screening among Medicare 's covered services for high risk-groups.
WASHINGTON, D.C. April 28, 2014 The American Cancer Society Cancer Action Network (ACS CAN) submitted comments to the Drug Enforcement Administration (DEA) today in opposition to the agency 's proposal to restrict access to hydrocodone combination products (HCPs).
WASHINGTON, D.C. April 24, 2014 Following is a statement from John R. Seffrin, chief executive of the American Cancer Society Cancer Action Network (ACS CAN), on the deeming regulation issued today by the Food & Drug Administration (FDA):
WASHINGTON, D.C. April 17, 2014 Six leading public health groups sent a letter to U.S.